Clinical-stage biopharmaceutical company Trevi Therapeutics (NASDAQ:TRVI) priced previously announced underwritten public offering of 17.4M shares at a public offering price of $5.75 per share.
Total proceeds are expected to be $100M.
Underwriters have a 30-day option to purchase up to 2.61M additional shares.
The offering is expected to close on or about June 5, 2025.
1 day ago
1
English (US) ·